Navigation Links
New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma

mately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. will co-promote VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
5. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
10. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
11. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
Post Your Comments:
(Date:7/28/2014)... and NEW PROVIDENCE, N.J. , July ... are invited to meet with Linde,s Healthcare division ... to be held at McCormick Place in ... "Hospitals demand nothing less than complete confidence in ... , Linde,s Healthcare Segment manager. "Linde understands the importance ...
(Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
(Date:7/28/2014)... , July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Second Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, ... PTWhere: www.isispharm.com How:Live on the Internet. Simply log ... to participate during the live event, a replay of ... at www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, ...
Breaking Medicine Technology:Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... 17, 2011 Reportlinker.com announces that a ... its catalogue: Depression Therapeutics ... 2018 http://www.reportlinker.com/p0656880/Depression-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Market Forecasts to 2018 ...
... Par Pharmaceutical, Inc., the wholly-owned subsidiary of Par ... announced that it filed a declaratory judgment complaint and ... in Washington, D.C. seeking to preserve Par,s First Amendment ... healthcare providers about the FDA-approved, on-label use of Par,s ...
Cached Medicine Technology:Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 2Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 3Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 4Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 5Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 6Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 7Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 8Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 9Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 10Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 2Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 3Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 4
(Date:7/28/2014)... 2014 This is a professional ... Tadalafil industry. The report firstly reviews the basic ... manufacturing technology. The report then explores global and ... specification, capacity, Production value, and market share etc. ... and China’s total market of Tadalafil by calculation ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Mahendra Trivedi, ... hosted the Trivedi Online Workshop ‘Consciousness is Power’ on ... (EST). During this workshop, participants from all over the ... of making a deeper connection to their inner guidance ... participants explored the various advantages of raising consciousness and ...
(Date:7/28/2014)... 2014 Scientists in Japan have completed ... blood test for the asbestos cancer mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Juntendo University Graduate School of Medicine say a new ... step above the old test. , “Particularly for ...
(Date:7/28/2014)... Wisconsin (PRWEB) July 28, 2014 ... business process outsourcing (BPO) for Fortune 500 brands, announced ... jobs across its locations in Wisconsin, California, Florida and ... be based at its Neenah campus. , A majority ... which have seasonal ramp-ups that require additional staffing in ...
(Date:7/28/2014)... Community Health Center of Snohomish County (CHC), ... services, has released an article designed to educate patients ... Founded in 1983, the health center has a strong ... that face barriers to obtaining high quality yet affordable ... the CHC, click here: http://www.chcsno.org/locations.ashx?p=1099 , The ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 4Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 3Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 3Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 3
... 30 years of HIV on an area once described as ... at a lecture hosted by the University of East Anglia ... production, with dire consequences for rural livelihoods, were originally predicted ... AIDS in central and south western Uganda. However, recent research ...
... , THURSDAY, Nov. 11 (HealthDay News) -- Researchers have pinpointed ... (AKI), a finding they believe could lead to a simple ... AKI usually doesn,t show obvious physical symptoms, which is ... The study found that urine samples from mice and ...
... 11, 2010 A new study from researchers in Colorado ... likely to undergo a screening colonoscopy than those who were ... female endoscopists seem to be common among women. In this ... that rates of screening colonoscopy can be increased by offering ...
... THURSDAY, Nov. 12 (HealthDay News) -- If you want to be ... people,s minds drifted from the task or activity at hand, they ... whatever they were doing. The human mind is uniquely capable ... to anticipate things that will happen, and to plan for things ...
... Gardner HealthDay Reporter , THURSDAY, Nov. 11 (HealthDay ... plans will come across some changes as they choose a ... open enrollment period, but experts say those differences won,t be ... Dec. 31, and any changes will take effect Jan. 1, ...
... "This ESMO-symposium will allow bed-side oriented oncologists to ... All presentations will have a clear focus towards ... the major consequences that new developments in cancer ... Soria, Symposium Co-Chair The ESMO Symposium on ...
Cached Medicine News:Health News:30 years on in the epicenter of the African AIDS epidemic 2Health News:Urine Markers May Reveal Kidney Damage Earlier 2Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 2Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 4Health News:Happiness Is a Focused Mind 2Health News:Happiness Is a Focused Mind 3Health News:Medicare Part D Changes Not Overwhelming, Experts Say 2Health News:Medicare Part D Changes Not Overwhelming, Experts Say 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: